

Weefselonderzoek bij longkanker

Rieneke Britstra

Klinisch patholoog Meander MC

4 november 2023

- wat doet een patholoog?
- weefsel soorten
- achter de schermen op het laboratorium
- hoe ontstaat kanker?
- verschillende soorten longkanker
- immuunhistochemie / PD-L1
- moleculair biologisch onderzoek
- verslaglegging / pathologie rapport

Inhoud

Hoe is de patholoog betrokken in het diagnostisch proces van longkanker

Pathologie is de studie (*logos*) van ziekten (*pathos*)

- beoordelen van losse cellen (cytologie) en weefsel (histologie)
- onderzoek naar de doodsoorzaak (obductie/autopsie)
- aanwezigheid bij multidisciplinaire overleg (MDO)



Wat doet een patholoog?

Weefselonderzoek bij longkanker

Cytologie: beoordelen van losse cellen

long spoelvocht
vocht achter de longen
cellen uit een lymfklier

urine
baarmoederhalsuitstrijkje




cellen uit de luchtpijp



Histologie: beoordelen van weefsel

(naald)biopt uit een afwijking die op een scan is gezien
weefsel verwijderd bij operatie

*kleine ingrepen bij de huisarts/huidarts
biopten verkregen uit de maag of darmen
knobbel in de borst*





← epitheel

← bindweefsel/steunweefsel

← kraakbeen

luchtpijp



Stap 1
- Afname van weefsel
> Transport afdeling
pathologie



Verwerking van het materiaal



Achter de schermen in het pathologie laboratorium (deel 1)

Verwerking op het laboratorium (inbedden)






Achter de schermen in het pathologie laboratorium (deel 2)

Verwerking op het laboratorium (snijden)



Achter de schermen in het pathologie laboratorium (deel 3)






Verwerking op het laboratorium (kleurmachine)



Achter de schermen in het pathologie laboratorium (deel 4)



● = 1 cel




Hoe ontstaat kanker?

Veel cellen bij elkaar worden zichtbaar op de scan

Ongeremde celdeling en groei


Kenmerken van kanker:

- Ongeremde celdeling en groei (toename van verkeerde cellen)
- Verstoring van de normale opbouw van het weefsel
- Mogelijkheid tot het verspreiden via bloedbaan of lymfebaan (uitzaaiing)



Diagnose longkanker


Hoe ziet (long)kanker er uit onder de microscoop?




Gaswisseling in de longen en in de weefsels

Longweefsel illustratie

Illustratie longblaasje




Longblaasje onder de microscoop





1 millimeter

Longweefsel onder de microscoop




Longkanker





Diagnose longkanker


Hoe ziet kanker er uit onder de




 = 1 tumorcel




niet-kleincellig longkanker (NSCLC)



adenocarcinoom






plaveiselcelcarcinoom






grootcellig carcinoom / nos

Hoe zien verschillende soorten longkanker er uit en waarom is het belangrijk deze te onderscheiden?




niet-kleincellig longkanker (NSCLC)

kleincellig longkanker (SCLC)



Hoe zien verschillende soorten longkanker er uit en waarom is het belangrijk deze te onderscheiden?

NSCLC




☐ Niet-kleincellige
longkanker

☒ PD-L1: %

☐ Kleincellige
longkanker

SCLC



☐ Adenocarcinoom


☐ Plaveiselcelcarcinoom

☐ Grootcellig
(ongedifferentieerd)
carcinoom


Moleculaire diagnostiek

- ☐ ALK
- ☐ BRAF
- ☐ EGFR
- ☐ HER2
- ☐ KRAS
- ☐ MET
- ☐ NRG1
- ☐ NTRK
- ☐ RET
- ☐ ROS1
- ☐ Anders:


niet-kleincellig carcinoom (NSCLC)




adenocarcinoom




plaveiselcelcarcinoom




grootcellig carcinoom / nos




TTF1



P40




TTF1



P40

Immuunhistochemie: subtypering



Immuunhistochemie: origine van de kanker / waar is de kanker ontstaan?




Image: NSCLC stained with PD-L1 primary antibody exhibiting a heterogeneous membrane staining pattern with various staining intensities: (A) partial membrane staining of tumor cell and (B) complete cell membrane staining (20× magnification).








Image: NSCLC stained with PD-L1 primary antibody exhibiting (A) strong staining of the tumor associated immune cells and (B) lack of PD-L1 staining of tumor cells (20× magnification).

PD-L1

Immuunhistochemie: behandeling



GGTCTGGATGC
CGGTCTGGATGC
GCCGTCTGGATG
GCCGTCTGGAT
GGCGGTCTGGAT
GGCGGTCTGGA
TCTATGCGGGCCCCCT
TCTATGCGGGCCCC
ATCTATGCGGGCC
TATCTATGCGGGC
TTATCTATGCGGG
CTTATCTATGCGGG



SNP: A → G






GTCTGGATGCT	TCTATGCGGGCCCCCT
GGTCTGGATGC	TCTATGCGGGCCCC
CGGTCTGGATGC	ATCTATGCGGGCC
GCGGTCTGGATG	TATCTATGCGGGC
GCGGTCTGGAT	TTATCTATGCGGG
GCGGTCTGGAT	CTTATCTATGCGGG
GGCGGTCTGGAT	CTTATCTATGCGG
GGCGGTCTGGA	CTTATCTATGCGG

GGCGGTCTAGATGCTTATCTATGCGGGCCCCCT



UMC Utrecht

Moleculair biologisch onderzoek (NGS = next generation sequencing)



- EGFR-mutatie
- KRAS-mutatie
- NTRK-fusie
- BRAF-mutatie
- ALK-fusie
- RET-fusie
- ROS-fusie
- HER2-mutatie
- MET-skippping
- NGR1-fusie
- geen mutatie


Het aantal DNA/RNA veranderingen per 1000 patiënten met stadium 4 niet-kleincellige longkanker type adenocarcinoom (Bron: PALGA en PATH)

Doelgerichte behandeling/ doelgerichte therapie


- Klinische gegevens
- Macroscopie
- Microscopie
- Aanvullend onderzoek (extra onderzoek, moleculair biologisch onderzoek)
- Conclusie (indien kwaadaardig: type kanker, PD-L1, moleculaire bevindingen)

pathologie
verslag


Pathologie verslag




pathologie
verslag




Vragen?



pathologie
verslag



CGGTCTGGATGC A'
GCGGTCTGGATG TA'
GCGGTCTGGAT TTA'
GCGGTCTGGAT CTTA'
GCGGTCTGGAT CTTA'
GCGGTCTGGA CTTA'



UMC Utrecht

